0001213900-26-035450
SEC filingCellyan Biotechnology Co., Ltd is a Cayman Islands holding company that operates through its Hong Kong subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited. The company provides OTC pharmaceutical cross-border e-commerce supply chain services and procurement and distribution services, primarily for Mainland Chinese customers accessing overseas OTC pharmaceutical products via e-commerce platforms. As of the date of the prospectus, the company's system has cataloged over 6,000 SKUs, including over 4,000 HKDOH-registered OTC SKUs. The company is not conducting an initial public offering for primary capital; this F-1 registration statement is for the resale of up to 12,499,986 Class A Ordinary Shares by existing selling shareholders from a recent private placement. The company will not receive any proceeds from these sales. The company is considered a 'controlled company' under Nasdaq rules, with Ms. Liying Wang holding approximately 95.63% of the voting power. The company's Class A Ordinary Shares are listed on the Nasdaq Capital Market under the symbol 'HKPD' but are currently not in compliance with the minimum bid price requirement, with a compliance period until July 13, 2026.